Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis

Study Overview
=================
Brief Summary
-----------------
The investigators assess the prevalence of airway disease associated with idiopathic pulmonary fibrosis in Korea, and evaluate the effect of these airway diseases on the symptoms and quality of life of patients with idiopathic pulmonary fibrosis.

Detailed Description
-----------------
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and limited to the lungs. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis. The main symptoms of patients with IPF are dyspnea on exertion and a persistent dry cough or mildly productive cough. In many IPF patients, cough is often the first symptom, preceding dyspnea on exertion sometimes by years. It affects upwards of 70-85% of patients with IPF. Chronic obstructive pulmonary disease (prevalence rate 4-18%) and asthma (prevalence rate 5.9-9.9%) are the airway disease whose main symptoms are also dyspnea and cough. To date, the effect of airway disease has not been well studied in patients with idiopathic pulmonary fibrosis, and the prevalence is unknown in Korea. Unlike idiopathic pulmonary fibrosis, airway disease is a treatable, modifiable disease, so treatment of these diseases may improve QOL in IPF patients. Therefore, this study's purpose is A. Identify the prevalence of airway disease in IPF patients B. Identify differences in QOL and symptoms according to presence of airway disease C. Identify the symptomatic improvement after active treatment for the airway diseases

Official Title
-----------------
Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis

Conditions
-----------------
Idiopathic Pulmonary Fibrosis, Airway Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Confirmation of Airway Disease combined with IPF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IPF patients Exclusion Criteria: Patients on systemic steroid Patients with acute exacerbation within the last 6 months PFT+BDR, MBPT contra-indication SpO2 < 90%
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Confirmation of Airway Disease combined with IPF|To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6 8 weeks later.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who have asthma combined with idiopathic pulmonary fibrosis | Confirmation of asthma : pulmonary function test with bronchodilator response or Methacholine provocation test | Through study completion, an average of 2 year | 
| Number of participants who have COPD combined with idiopathic pulmonary fibrosis | Confirmation of COPD : pulmonary function test with bronchodilator response | Through study completion, an average of 2 year | 
| Number of participants who have Eosinophilic bronchitis combined with idiopathic pulmonary fibrosis | Confirmation of Eosinophilic bronchitis : pulmonary function test with bronchodilator response, induced sputum | Through study completion, an average of 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The difference of CAT scores between patients with airway disease and those without airway disease. | Quality of life : COPD assessment test(CAT) | baseline and after treating the airway disease for 6 8 weeks | 
| The difference of SGRQ scores to assess quality of life between patients with airway disease and those without airway disease. | Quality of life : St George's Respiratory Questionnaire(SGRQ) | baseline and after treating the airway disease for 6 8 weeks | 
| The difference of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease. | Symptom severity : mMRC | baseline and after treating the airway disease for 6 8 weeks | 
| The difference of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease. | Symptom severity : 6 minute walking test(6MWT) | baseline and after treating the airway disease for 6 8 weeks | 
| The difference of EQ-5D-VAS scores to assess symptom severity between patients with airway disease and those without airway disease. | Symptom severity : EQ-5D-VAS | baseline and after treating the airway disease for 6 8 weeks | 
| The difference of CQLQ scores to assess symptom severity between patients with airway disease and those without airway disease. | Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ) | baseline and after treating the airway disease for 6 8 weeks | 
| Checking the improvement of CAT score to assess the quality of life between patients with airway disease and those without airway disease | Quality of life : COPD assessment test(CAT) | After treating the airway disease for 6 8 weeks | 
| Checking the improvement of SGRQ score to assess the quality of life between patients with airway disease and those without airway disease | Quality of life : St George's Respiratory Questionnaire(SGRQ) | After treating the airway disease for 6 8 weeks | 
| Checking the improvement of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease | Symptom severity : mMRC | After treating the airway disease for 6 8 weeks | 
| Checking the improvement of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease | Symptom severity : 6 minute walking test(6MWT) | After treating the airway disease for 6 8 weeks | 
| Checking the improvement of EQ-5D-VAS score to assess symptom severity between patients with airway disease and those without airway disease | Symptom severity : EQ-5D-VAS | After treating the airway disease for 6 8 weeks | 
| Checking the improvement of CQLQ to assess symptom severity between patients with airway disease and those without airway disease | Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ) | After treating the airway disease for 6 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Idiopathic Pulmonary Fibrosis, Airway Disease